New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free
Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Friday, November 13, 2026

Back to the front page

From X

@ACapitalLP

A Capital on X

Starting to think $MGM is absurdly cheap here at ~$29… Market extrapolating a terrible Vegas quarter (EBITDAR -12%, RevPAR -8%) while largely ignoring Macau share gains, BetMGM profitability and Osaka optionality. More interestingly, the buyback window reopens 10/30 with $1.4bn remaining (~20% of market cap). Management willing to take leverage from ~4x to 4.5–5x. Vegas weakness is real, but the marginal buyer is potentially the company itself, with substantial firepower at precisely the wrong price for sellers. Note: Barry Diller ($PPLI) was willing to pay $48/share for this exact same company a few months ago… Thoughts welcome.
@StableBread

Fajasy on X

If First Solar $FSLR wins its patent case at the U.S. International Trade Commission (ITC), TOYO Co., Ltd’s $TOYO cells could be barred from the U.S. First Solar filed a complaint at the ITC on February 24, 2026, claiming certain TOPCon cells, a common high-efficiency silicon cell design, infringe one of its patents. The ITC voted on March 26 to open Investigation 337-TA-1494, naming $TOYO, its Texas subsidiary, VSUN (the Vietnamese panel maker $TOYO was carved out of), and VSUN’s U.S. arm among 47 respondents. The ITC’s target date is November 15, 2027. The patent case won’t be decided before late 2027, but it’s another way $TOYO’s cells could be stopped at the border. I’m not worried about the patent case yet, since the ITC’s target date is more than a year away and dozens of other respondents face the same claim.

Investor Letters

All letters

QXO Inc Earnings Update: Q3 2026

QXO's Q3 sales rose 79% to $4.9 billion after TopBuild and Kodiak acquisitions, while acquisition debt lifted interest expense to $163…

QXO $13B
SixSigmaCapital: Navigating the Financial Markets 2 clicks

Cerrado Gold: Research Note

Cerrado Gold will acquire Argentina’s Manantial Espejo mine from Pan American Silver for $20 million and targets a 2027 restart funded by…

PAAS $16B
Atrium Research - Equity Research 2 clicks

Qure Anniversary Update

UniQure’s Huntington’s disease BLA has a May 1, 2027 priority-review date, with an FDA advisory committee expected in late first quarter.

QURE $1.7B
Triple S Special Situations Investing 2 clicks

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

YouTube 4

Blogs 15

Seeking Alpha 88 of 290

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.